The First Two, Check and Check "Amarantus is a
Post# of 30028
Posted On: 12/11/2014 10:59:58 PM
The First Two, Check and Check
"Amarantus is a truly exciting company with several potential blockbuster product candidates targeting significant unmet needs," stated Dr. Brownell. "I look forward to working closely with this team of visionaries with the goal of providing new, paradigm-changing treatment options for patients."
Dr. Brownell is the co-founder of ZephyrBiotech LLC, a project management firm dedicated to advancing therapeutic candidates through development to key inflection points for clients. Earlier, she was a founding member, head of project management and senior director of Aerovance, Inc., a venture-backed biotechnology company spun out from Bayer Healthcare , where she created and managed effective team processes to bring product candidates into full scale clinical Phase 1 and 2 development. Prior to Aerovance, Dr. Brownell acted as head of project management for Bayer's Biotechnology Unit, where she integrated project strategies to meet therapeutic and market needs. Other roles included building and negotiating partnerships with third parties to support development programs , leading research teams through early bench-to-clinic development phases, as well as entrepreneurial investment experience with Angel's Forum (www.angelsforum.com). Dr. Brownell received her M.S., M.Phil. and Ph.D. in biology from Yale University and her B.S. in biology from Allegheny College.
Read More: http://investorshangout.com/post/view?id=2433...z3LeV6PE7D
"Amarantus is a truly exciting company with several potential blockbuster product candidates targeting significant unmet needs," stated Dr. Brownell. "I look forward to working closely with this team of visionaries with the goal of providing new, paradigm-changing treatment options for patients."
Dr. Brownell is the co-founder of ZephyrBiotech LLC, a project management firm dedicated to advancing therapeutic candidates through development to key inflection points for clients. Earlier, she was a founding member, head of project management and senior director of Aerovance, Inc., a venture-backed biotechnology company spun out from Bayer Healthcare , where she created and managed effective team processes to bring product candidates into full scale clinical Phase 1 and 2 development. Prior to Aerovance, Dr. Brownell acted as head of project management for Bayer's Biotechnology Unit, where she integrated project strategies to meet therapeutic and market needs. Other roles included building and negotiating partnerships with third parties to support development programs , leading research teams through early bench-to-clinic development phases, as well as entrepreneurial investment experience with Angel's Forum (www.angelsforum.com). Dr. Brownell received her M.S., M.Phil. and Ph.D. in biology from Yale University and her B.S. in biology from Allegheny College.
Read More: http://investorshangout.com/post/view?id=2433...z3LeV6PE7D
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼